Comparative analysis of marketed factor VIII products: comment

We read with interest the paper by Azengruber and colleagues recently published in the journal. The authors reported significant variation among the different recombinant concentrates in terms of content of soluble protein aggregates and subvisible particles. This could be important in explaining the differential immunogenicity, in terms of inhibitor development, among recombinant concentrates. We were, however, disappointed that the authors do not name the nine brands of recombinant FVIII concentrates they studied. By convention in scientific literature, authors are required to name their reagents and their source. We can not see any reason why the names of the concentrates were withheld and invite the authors to name the products now. This is particularly relevant as the studies cited by Anzengruber et al to demonstrate the different rates of inhibitor incidence relative to product type do cite the products used. This article is protected by copyright. All rights reserved.